Article thumbnail

A Screening Method for the ALK Fusion Gene in NSCLC

By Yoshiko Murakami, Tetsuya Mitsudomi and Yasushi Yatabe


Lung cancer research has recently made significant progress in understanding the molecular pathogenesis of lung cancer and in developing treatments for it. Such achievements are directly utilized in clinical practice. Indeed, the echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (ALK) fusion gene was first described in non-small cell lung cancer in 2007, and a molecularly targeted drug against the fusion was approved in 2011. However, lung cancer with the ALK fusion constitutes only a small fraction of lung cancers; therefore, efficient patient selection is crucial for successful treatment using the ALK inhibitor. Currently, RT-PCR, fluorescent in situ hybridization (FISH), and immunohistochemistry are commonly used to detect the ALK fusion. Although FISH is currently the gold standard technique, there are no perfect methods for detecting these genetic alterations. In this article, we discuss the advantages and disadvantages of each method and the possible criteria for selecting patients who are more likely to have the ALK fusion. If we can successfully screen patients, then ALK inhibitor treatment will be the best example of personalized therapy in terms of selecting patients with an uncommon genotype from a larger group with the same tumor phenotype. In other words, the personalized therapy may offer a new challenge for current clinical oncology

Topics: Oncology
Publisher: Frontiers Research Foundation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008).EML4-ALKfusionlungcancer: a rare acquired event.
  2. (2008). A mouse model for EML4-ALK-positive lung cancer.
  3. (2010). A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
  4. (2012). A screening method for the ALK fusion gene in NSCLC.
  5. (2011). accepted: 19
  6. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
  7. (2006). Advances in chemotherapy of non-small cell lung cancer.
  8. (2010). Clinicopathologic features of nonsmall-cell lung cancer with EML4-ALK fusion gene.
  9. (2011). Comprehensive histologic analysisofALK-rearrangedlungcarcinomas.
  10. (2004). EGFR mutations in lungcancer:correlationwithclinical responsetogefitinibtherapy.Science 304,
  11. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
  12. (2008). EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
  13. (2008). EML4-ALK fusion transcripts, but no NPM-, TPM3-,CLTC-,ATIC-,orTFG-ALK fusion transcripts, in non-small cell lung carcinomas.
  14. (2009). EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
  15. (2012). Frontiers in Oncology | Cancer MolecularTargets andTherapeutics
  16. (2007). Global survey of phosphotyrosinesignalingidentifiesoncogenickinasesinlungcancer.
  17. (2007). Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer.
  18. (2009). KIF5B-ALK, a novel fusion oncokinase identified byanimmunohistochemistry-based diagnostic system for ALK-positive lung cancer.
  19. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
  20. (2010). The biology and treatment of EML4-ALK nonsmall cell lung cancer.
  21. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits noncommercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
  22. (2009). Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
  23. W.,andIafrate,A.J.(2010).Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.